At Cortado Ventures we are proud to announce closing a major investment in Oklahoma City founded Sensulin. Led by University of Oklahoma graduate Mike Moradi, Sensulin is a biopharmaceutical company that is developing a glucose-responsive insulin for type 1 and type 2 diabetes. As a fellow Sooner and board member of the Harold Hamm Diabetes Center, I am proud to mark this milestone of a local venture capital firm backing a homegrown biotech company.
Sensulin aims to substantially lower the risk of hypoglycemia, and reduce the long-term complications associated with diabetes (eye & kidney disease, etc), while reducing the number of required daily injections. Ultimately, Sensulin may eliminate the need for separate basal and mealtime insulin, offer a substantial improvement in the standard care, and most importantly, give those with diabetes a chance at a normal life.